Trial Profile
Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Anti-CD45 monoclonal antibody (Primary) ; Fludarabine; Tacrolimus
- Indications Metabolic disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms MAID
- 25 Sep 2015 New trial record